Skip to main content

Table 2 Univariate Cox regression of 13 genes and available clinical variables

From: DNA methylation gene-based models indicating independent poor outcome in prostate cancer

  HRa(95% CI) LRbχ2 Adjustedc P -value Harrell’s c-index Total Nod Event Noe
Gleason score 2.33 (1.99, 2.73) 105.3 2.2*10-16 0.79 367 99
Extent of disease 1.27 (1.21, 1.34) 80.1 2.2*10-16 0.76 367 99
PSA 1.36 (1.28, 1.45) 68.9 6.3*10-16 0.76 367 99
Age 1.04 (1.00, 1.09) 3.2 0.08 0.52 367 99
MAL 1.28 (1.17, 1.40) 25.4 2.0*10-6 0.64 352 95
DPYS 1.20 (1.12, 1.29) 24.2 2.9*10-6 0.65 344 95
TIG1 1.25 (1.14, 1.36) 20.9 1.4*10-5 0.65 350 90
GSTP1 1.17 (1.08, 1.26) 16.4 1.2*10-4 0.62 357 98
APC 1.18 (1.08, 1.29) 10.9 0.002 0.61 365 99
PDLIM4 1.16 (1.06, 1.26) 10.9 0.002 0.60 365 98
RARB 1.13 (1.04, 1.24) 7.7 0.01 0.60 351 98
SLIT2 1.17 (1.05, 1.31) 6.6 0.016 0.58 350 94
SFN 1.13 (1.02, 1.25) 5.8 0.023 0.57 363 99
CCND2 1.12 (1.02, 1.23) 5.2 0.029 0.56 364 99
HIN1 1.09 (1.01, 1.18) 5.1 0.029 0.59 350 97
HSPB1 1.12 (1.02, 1.22) 5.0 0.029 0.52 349 91
SERPINB5 0.95 (0.83, 1.08) 0.7 0.408 0.53 357 95
  1. aThe hazard ratios were calculated per 10 units increase in age, PSA, extent of disease and gene methylation while it is per unit increase in Gleason score, i.e. 4 through 10.
  2. bLR = likelihood ratio test.
  3. cThe Benjamin and Hochberg step-up procedure for controlling false discovery rate (FDR) was applied with FDR of 5%.
  4. dThe total number of patients for which DNAme was successfully measured. The clinical variables were available for all men included in the study.
  5. eThe number of patients for which a DNAme result was obtained and who died of prostate cancer.